UY35402A - ?compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis?. - Google Patents

?compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis?.

Info

Publication number
UY35402A
UY35402A UY0001035402A UY35402A UY35402A UY 35402 A UY35402 A UY 35402A UY 0001035402 A UY0001035402 A UY 0001035402A UY 35402 A UY35402 A UY 35402A UY 35402 A UY35402 A UY 35402A
Authority
UY
Uruguay
Prior art keywords
fibrosis
alkenyl
alkyl
treatment
aromatic compounds
Prior art date
Application number
UY0001035402A
Other languages
English (en)
Inventor
Gagnon Lyne
Laurin Pierre
Grouix Brigitte
Zacharie Boulos
Abbott Shaun
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of UY35402A publication Critical patent/UY35402A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

La presente invención se refiere a compuestos de: o una sal farmacéuticamente aceptable de este, en donde A es alquilo C5, alquilo C6, alquenilo C5, alquenilo C6, C(O)-(CH2)n-CH3 o CH(OH)-(CH2)n-CH3 en donde n es 3 o 4; R1 es H, F u OH; R2 es alquilo C5, alquilo C6, alquenilo C5, alquenilo C6, C(O)-(CH2)n-CH3 o CH(OH)-(CH2)n-CH3 en donde n es 3 o 4; R3 es H, F, OH o CH2Ph; R4 es H, F u OH; Q es 1 ) (CH2)mC(O)OH en donde m es 1 o 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)-C(O)OH, 5) CF2-C(O)OH o 6) C(O)-C(O)OH; y a composiciones que l os contienen y el método de uso de estos para la prevención o el tratamiento de diversas enfermedades y afecciones fibróticas en los sujetos, incluida la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel, la fibrosis renal, la fibrosis del páncreas, la esclerosis sistémica, la fibrosis cardíaca o la degeneración macular.
UY0001035402A 2013-03-15 2014-03-13 ?compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis?. UY35402A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361798269P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
UY35402A true UY35402A (es) 2014-10-31

Family

ID=51535669

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035402A UY35402A (es) 2013-03-15 2014-03-13 ?compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis?.

Country Status (26)

Country Link
US (3) US10023518B2 (es)
EP (1) EP2970089B1 (es)
JP (1) JP6448562B2 (es)
KR (1) KR102196721B1 (es)
CN (2) CN105189438A (es)
AR (1) AR095429A1 (es)
AU (1) AU2014231648B2 (es)
BR (1) BR112015022008A2 (es)
CA (1) CA2905621C (es)
CL (1) CL2015002535A1 (es)
DK (1) DK2970089T3 (es)
EA (1) EA030651B1 (es)
ES (1) ES2741439T3 (es)
HK (1) HK1220440A1 (es)
IL (1) IL241178B (es)
MX (1) MX2015011878A (es)
MY (1) MY180305A (es)
NZ (1) NZ712797A (es)
PH (1) PH12015502011A1 (es)
PL (1) PL2970089T3 (es)
PT (1) PT2970089T (es)
SG (1) SG11201507408XA (es)
TW (1) TWI689490B (es)
UY (1) UY35402A (es)
WO (1) WO2014138906A1 (es)
ZA (1) ZA201507061B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
CN106999456B (zh) * 2014-10-10 2020-07-10 里米诺生物科学有限公司 用于预防和治疗骨质疏松症的被取代的芳族化合物和药物组合物
WO2016054726A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
RU2728782C2 (ru) 2014-11-12 2020-07-31 Лиминал Байосайенсиз Лимитед Замещенные ароматические соединения и фармацевтические композиции для ауторепарации и регенерации ткани
MX2017011903A (es) * 2015-03-18 2018-05-22 Vectus Biosystems Ltd Composiciones para el tratamiento de enfermedades renales y/o hepaticas.
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
US20190144547A1 (en) 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
CN108472276B (zh) * 2016-05-19 2021-07-23 长弘生物科技股份有限公司 用于延缓肺纤维化的发病及/或治疗肺纤维化的药剂
WO2018107686A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种治疗动脉粥样硬化及其并发症的方法
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR102126389B1 (ko) * 2018-09-14 2020-06-25 셀라이온바이오메드 주식회사 벤즈히드릴티오 아세트아미드 화합물을 유효성분으로 포함하는 간 질환의 예방 또는 치료용 조성물
CN116568291A (zh) * 2020-10-06 2023-08-08 殷格纽制药有限公司 取代的芳香族化合物及其药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183519A1 (en) * 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
AU2007267612A1 (en) * 2006-05-26 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted carboxylic acid compounds
US20110046050A1 (en) * 2007-02-08 2011-02-24 Emisphere Technologies, Inc. Phenylalkylcarboxylic acid delivery agents
SG175855A1 (en) * 2009-05-04 2011-12-29 Prometic Biosciences Inc Substituted aromatic compounds and pharmaceutical uses thereof
JP5844251B2 (ja) * 2009-05-04 2016-01-13 プロメティック・バイオサイエンシーズ・インコーポレイテッドProMetic BioSciences Inc. 3−ペンチルフェニル酢酸の塩およびその薬学的使用
AT509045B1 (de) 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale

Also Published As

Publication number Publication date
CN110105200A (zh) 2019-08-09
ES2741439T3 (es) 2020-02-11
AR095429A1 (es) 2015-10-14
CL2015002535A1 (es) 2016-03-28
MX2015011878A (es) 2016-06-07
CN105189438A (zh) 2015-12-23
MY180305A (en) 2020-11-27
JP6448562B2 (ja) 2019-01-09
US20160039736A1 (en) 2016-02-11
EP2970089B1 (en) 2019-05-08
WO2014138906A1 (en) 2014-09-18
CA2905621C (en) 2021-06-29
ZA201507061B (en) 2017-03-26
SG11201507408XA (en) 2015-10-29
DK2970089T3 (da) 2019-08-05
NZ712797A (en) 2020-08-28
JP2016512202A (ja) 2016-04-25
CA2905621A1 (en) 2014-09-18
PT2970089T (pt) 2019-09-04
US11524930B2 (en) 2022-12-13
HK1220440A1 (zh) 2017-05-05
CN110105200B (zh) 2022-04-12
AU2014231648B2 (en) 2018-02-08
US10023518B2 (en) 2018-07-17
US20180237374A1 (en) 2018-08-23
PH12015502011B1 (en) 2016-01-11
TW201441186A (zh) 2014-11-01
EA030651B1 (ru) 2018-09-28
EP2970089A4 (en) 2016-10-12
KR20160051676A (ko) 2016-05-11
IL241178B (en) 2020-09-30
US20200172462A1 (en) 2020-06-04
BR112015022008A2 (pt) 2021-05-25
EP2970089A1 (en) 2016-01-20
IL241178A0 (en) 2015-11-30
PL2970089T3 (pl) 2020-01-31
KR102196721B1 (ko) 2020-12-30
EA201591775A1 (ru) 2016-05-31
PH12015502011A1 (en) 2016-01-11
US10550066B2 (en) 2020-02-04
TWI689490B (zh) 2020-04-01
AU2014231648A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
UY35402A (es) ?compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis?.
UY35401A (es) ?compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca?.
CL2022000619A1 (es) Oxinitruro de piridina, método para su preparación y uso de este
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
CL2020001090A1 (es) Compuesto de pirimidina como inhibidor de las janocinasas.
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
UY36207A (es) Inhibidores de la syk
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
AR071788A1 (es) Derivados de 3-aminocarbazol, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos para tratar y/o prevenir trastornos asociados con la produccion de prostaglandina e2(pge2), tales como aterosclerosis, artritis, artrosis y tumores, entre otros.
UY35376A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR107828A1 (es) 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k
DOP2014000133A (es) Triazolopiridinas sustituidas
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
PE20200698A1 (es) Gel que comprende clorhexidina
PE20200341A1 (es) Composiciones y compuestos terapeuticos y metodos para utilizarlos
BR112017020081A2 (pt) análogos deuterados de etifoxina, seus derivados e usos dos mesmos
BR112016025126A2 (pt) formulação líquida compreendendo composto neutralizante de gm-csf
AR102246A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis, usos
AR107937A1 (es) Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer
AR054113A1 (es) Forma cristalina solida de pantoprazol como acido libre, sales derivadas del mismo y proceso para su preparacion
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento
CL2017001602A1 (es) Derivados de fumagilol.
AR097890A1 (es) Compuestos de urea

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220817